MGMT and central nervous system cancer: Since MGMT expression is inhibited by methylation of its promoter, and MGMT promoter methylation correlates with enhanced overall survival (OS) and progression free survival (PFS), the methylation status of MGMT is used as a predictive marker for glioma therapy [16].